Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

OBJECTIVES: Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants. METHODS: Two randomized, placebo-controlled, double-blind st...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmers, Maarten, Van Broeck, Bianca, Ramael, Steven, Slemmon, John, De Waepenaert, Katja, Russu, Alberto, Bogert, Jennifer, Stieltjes, Hans, Shaw, Leslie M., Engelborghs, Sebastiaan, Moechars, Dieder, Mercken, Marc, Liu, Enchi, Sinha, Vikash, Kemp, John, Van Nueten, Luc, Tritsmans, Luc, Streffer, Johannes Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651349/
https://www.ncbi.nlm.nih.gov/pubmed/29067308
http://dx.doi.org/10.1016/j.trci.2016.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651349/
https://www.ncbi.nlm.nih.gov/pubmed/29067308
http://dx.doi.org/10.1016/j.trci.2016.08.001

Ejemplares similares